Vertex Pharmaceuticals Inc
NASDAQ:VRTX

Watchlist Manager
Vertex Pharmaceuticals Inc Logo
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Watchlist
Price: 441.36 USD 0.56% Market Closed
Market Cap: 112B USD
Section:
 

Relative Value

The Relative Value of one VRTX stock under the Base Case scenario is 337.96 USD. Compared to the current market price of 441.36 USD, Vertex Pharmaceuticals Inc is Overvalued by 23%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

VRTX Relative Value
Base Case
337.96 USD
Overvaluation 23%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

9.6
P/S
P/S
Price to Sales
9.6
vs History
42
vs Industry
40
Median 3Y
9.9
Median 5Y
9.4
Industry
8.1
Forward
9.2
More Details
30.5
P/E
P/E
Price to Earnings
30.5
vs History
7
vs Industry
6
Median 3Y
25.8
Median 5Y
24.9
Industry
23.7
Forward
23.6
More Details
30.2
P/OCF
P/OCF
Price to OCF
30.2
vs History
7
vs Industry
6
Median 3Y
20.7
Median 5Y
20.7
Industry
22.6
More Details
33.7
P/FCFE
P/FCFE
Price to FCFE
33.7
vs History
7
vs Industry
5
Median 3Y
22.3
Median 5Y
22.3
Industry
25.7
More Details
6.5
P/B
P/B
Price to Book Value
6.5
vs History
26
vs Industry
12
Median 3Y
6.3
Median 5Y
6.2
Industry
3.3
More Details
9
EV/S
EV/S
Enterprise Value to Sales
9
vs History
33
vs Industry
34
Median 3Y
9.2
Median 5Y
8.4
Industry
8.4
Forward
8.7
More Details
10.5
EV/GP
EV/GP
Enterprise Value to Gross Profit
10.5
vs History
31
vs Industry
33
Median 3Y
10.6
Median 5Y
9.5
Industry
10.4
More Details
22.3
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
22.3
vs History
25
vs Industry
6
Median 3Y
21.5
Median 5Y
19.3
Industry
5.9
Forward
19.3
More Details
23.3
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
23.3
vs History
23
vs Industry
5
Median 3Y
22.4
Median 5Y
20.3
Industry
6.4
Forward
19.8
More Details
28.5
EV/OCF
EV/OCF
Enterprise Value to OCF
28.5
vs History
7
vs Industry
5
Median 3Y
18
Median 5Y
18
Industry
8.2
More Details
31.7
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
31.7
vs History
3
vs Industry
5
Median 3Y
19.1
Median 5Y
19.1
Industry
6.4
More Details
7.3
EV/IC
EV/IC
Enterprise Value to IC
7.3
vs History
80
vs Industry
19
Median 3Y
8.1
Median 5Y
8.6
Industry
5.8
More Details

Multiples Across Competitors

VRTX Competitors Multiples
Vertex Pharmaceuticals Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
112.1B USD 9.6 30.5 22.3 23.3
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 198 755.5 -162 541.6 -197 377.4 -195 125.1
US
Abbvie Inc
NYSE:ABBV
378.8B USD 6.4 161.3 15.7 22.3
US
Amgen Inc
NASDAQ:AMGN
177.8B USD 4.9 25.4 18.3 18.3
US
Gilead Sciences Inc
NASDAQ:GILD
155.1B USD 5.3 19.1 12.9 12.9
US
Epizyme Inc
F:EPE
94.1B EUR 2 060 -525.7 -572.4 -557.1
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.2B USD 5.4 16.9 16 18.2
AU
CSL Ltd
ASX:CSL
85B AUD 3.7 18.9 12.8 15.9
NL
argenx SE
XBRU:ARGX
42.4B EUR 13.7 32.1 55.1 56.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.3B USD 14.8 1 086.8 146.4 177.6
US
Seagen Inc
F:SGT
39.3B EUR 19.8 -60.8 -65.6 -59.2
P/S Multiple
Revenue Growth P/S to Growth
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Average P/S: 3 109 172.6
9.6
10%
1
FR
Pharnext SCA
OTC:PNEXF
34 198 755.5
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.4
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.9
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
5.3
4%
1.3
US
E
Epizyme Inc
F:EPE
2 060
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.4
6%
0.9
AU
CSL Ltd
ASX:CSL
3.7
5%
0.7
NL
argenx SE
XBRU:ARGX
13.7
49%
0.3
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
14.8
46%
0.3
US
S
Seagen Inc
F:SGT
19.8
30%
0.7
P/E Multiple
Earnings Growth PEG
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Average P/E: 173.9
30.5
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -162 541.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
161.3
89%
1.8
US
Amgen Inc
NASDAQ:AMGN
25.4
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
19.1
190%
0.1
US
E
Epizyme Inc
F:EPE
Negative Multiple: -525.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.9
10%
1.7
AU
CSL Ltd
ASX:CSL
18.9
11%
1.7
NL
argenx SE
XBRU:ARGX
32.1
40%
0.8
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 086.8
N/A N/A
US
S
Seagen Inc
F:SGT
Negative Multiple: -60.8 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Average EV/EBITDA: 37.4
22.3
16%
1.4
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -197 377.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.7
14%
1.1
US
Amgen Inc
NASDAQ:AMGN
18.3
11%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
12.9
7%
1.8
US
E
Epizyme Inc
F:EPE
Negative Multiple: -572.4 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16
11%
1.5
AU
CSL Ltd
ASX:CSL
12.8
8%
1.6
NL
argenx SE
XBRU:ARGX
55.1
810%
0.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
146.4
N/A N/A
US
S
Seagen Inc
F:SGT
Negative Multiple: -65.6 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Average EV/EBIT: 43.1
23.3
16%
1.5
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 125.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.3
30%
0.7
US
Amgen Inc
NASDAQ:AMGN
18.3
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.9
12%
1.1
US
E
Epizyme Inc
F:EPE
Negative Multiple: -557.1 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.2
13%
1.4
AU
CSL Ltd
ASX:CSL
15.9
11%
1.4
NL
argenx SE
XBRU:ARGX
56.6
N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
177.6
N/A N/A
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.2 N/A N/A

See Also

Summary
VRTX intrinsic value, competitors valuation, and company profile.
DCF Valuation
VRTX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
VRTX stock valuation using valuation multiples.
Wall Street Estimates
VRTX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
VRTX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 310,300+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.